Upgrade to SI Premium - Free Trial

TD Cowen: 'Rocket's protocol modifications may be mitigating prior risks'

August 3, 2026 9:03 AM
TD Cowen analyst Tara Bancroft reiterated a Hold rating on Rocket Pharmaceuticals (NASDAQ: RCKT).The analyst comments "Safety was the key ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments